Viewing 17 results

You are viewing the category of Dermatology

Dermatology
Assessing Subjective Burden in Patients with Atopic Dermatitis

Assessing Subjective Burden in Patients with Atopic Dermatitis
By :
Pro.Jonathan & Prof.Melinda
Dermatology
Assessing Clinical Severity in Patients with Atopic Dermatitis

Assessing Clinical Severity in Patients with Atopic Dermatitis
By :
Pro.Jonathan & Prof.Melinda
Dermatology
Assessing lack of treatment response in patients with Atopic Dermatitis

Assessing lack of treatment response in patients with Atopic Dermatitis
By :
Pro.Jonathan & Prof.Melinda
Dermatology
Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?

Targeting IL-13: Does It Scratch the Itch in Atopic Dermatitis?
By :
Dr. Sarina Elmariah
Dermatology
The AD Saga Measuring Eligibility for Systemic Therapy

The AD Saga Measuring Eligibility for Systemic Therapy
By :
Pro.Jonathan & Prof.Melinda
Dermatology
Taltz real patient experience

Taltz real patient experience
By :
Prof.Ayman Elgendi
Dermatology
Taltz have Connected Clinical trials with Real World Evidence (RWE)

Taltz have Connected Clinical trials with Real World Evidence (RWE)
By :
Dr.Yousef Binamer
Dermatology
Taltz in the real-world: Month12 out comes from the PSoHO study.

Taltz in the real-world: Month12 out comes from the PSoHO study.
By :
Lilly Saudi Arabia
Dermatology
Treating severe AA with Olumiant (patient case)

Treating severe AA with Olumiant (patient case)
By :
Dr. Sergio Galván
Dermatology
Olumiant efficacy in AA – results from BRAVE-AA1 & BRAVE-AA2

Olumiant efficacy in AA – results from BRAVE-AA1 & BRAVE-AA2
By :
Lilly Saudi Arabia
Dermatology
Ixekizumab (Taltz) in Real World Patients!

Ixekizumab (Taltz) in Real World Patients!
By :
Professor Ayman Elgendi
Dermatology
Real World Evidence & Psoriasis Study of Health Outcomes

Real World Evidence & Psoriasis Study of Health Outcomes
By :
Dr. Yousef Binamer
Show More

Call Center          920008161

[email protected]

About Us
Support
Technical Requirements
VMA Team
Partner
© VMA 2025